NCT03790670View on ClinicalTrials.gov

Biomarker Assessments of Leukine During Treatment of Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions
Parkinson Disease
Interventions
DRUG

sargramostim

Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors
lead

University of Nebraska

OTHER

NCT03790670 - Biomarker Assessments of Leukine During Treatment of Parkinson's Disease | Biotech Hunter | Biotech Hunter